Effektivitet og sikkerhed for palifermin blev fastslået i et randomiseret, dobbeltblindt, placebo kontrolleret forsøg, hvor patienterne modtog højdosis cytotoksisk behandling bestående af fraktioneret helkropsbestråling (12 Gy total dosis), højdosis etoposid (60 mg/ kg) og højdosis cyclofosfamid (100 mg/ kg) efterfulgt af PBPC- understøtning til behandling af hæmatologiske maligniteter (Non- Hodgkins lymfom (NHL), Hodgkin’ s sygdom, Akut Myeloid Leukæmi (AML), Akut Lymfocytisk Leukæmi (ALL), Kronisk Myeloid Leukæmi (CML), Kronisk Lymfocytisk Leukæmi (CLL) eller multipelt myelom).
Efficacy and safety of palifermin were established in a randomised, double-blind, placebo-controlled study in which patients received high-dose cytotoxic therapy consisting of fractionated total-body irradiation (12 Gy total dose), high-dose etoposide (60 mg/ kg), and high-dose cyclophosphamide (100 mg/ kg) followed by PBPC support for the treatment of haematological malignancies ((Non- Hodgkin’ s Lymphoma (NHL), Hodgkin’ s disease, Acute Myeloid Leukaemia (AML), Acute Lymphocytic Leukaemia (ALL), Chronic Myeloid Leukaemia (CML), Chronic Lymphocytic Leukaemia (CLL), or multiple myeloma).